GoodRx Says Q1, Q2 2026 Financials Can No Longer Be Relied Upon After Understating Pharma Direct Revenue By $29.773M; Expects Material Weakness
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001809519/000180951926000184/gdrx-20261027.htm
Share
Why It Matters
GoodRx found a big counting mistake in their money reports. Now you should watch closely to see if the company fixes things and regains trust.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.